Analyzing Century Therapeutics (NASDAQ:IPSC) & Prothena (NASDAQ:PRTA)

Prothena (NASDAQ:PRTA) and Century Therapeutics (NASDAQ:IPSC) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, risk, dividends and institutional ownership.

Risk & Volatility

Prothena has a beta of -0.2, indicating that its share price is 120% less volatile than the S&P 500. Comparatively, Century Therapeutics has a beta of 1.78, indicating that its share price is 78% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Prothena and Century Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prothena	1	1	4	1	2.71
Century Therapeutics	1	2	4	0	2.43

Prothena presently has a consensus price target of $20.00, suggesting a potential upside of 129.10%. Century Therapeutics has a consensus price target of $4.75, suggesting a potential upside of 172.99%. Given Century Therapeutics’ higher possible upside, analysts clearly believe Century Therapeutics is more favorable than Prothena.

Profitability

This table compares Prothena and Century Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Prothena	-45.44%	-9.98%	-9.08%
Century Therapeutics	N/A	-49.51%	-38.09%

Insider and Institutional Ownership

97.1% of Prothena shares are held by institutional investors. Comparatively, 50.2% of Century Therapeutics shares are held by institutional investors. 10.4% of Prothena shares are held by insiders. Comparatively, 2.4% of Century Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares Prothena and Century Therapeutics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prothena	$9.68 million	46.31	-$244.09 million	($0.48)	-18.19
Century Therapeutics	$109.16 million	2.89	-$9.58 million	($0.93)	-1.87

Century Therapeutics has higher revenue and earnings than Prothena. Prothena is trading at a lower price-to-earnings ratio than Century Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Prothena beats Century Therapeutics on 8 of the 14 factors compared between the two stocks.

About Prothena

Prothena Corporation plc is a clinical-stage biotechnology company developing treatments for diseases associated with protein misfolding and dysfunction. Its research focuses on using antibodies and other biologic approaches to target proteins implicated in neurological and systemic disorders. The company’s pipeline has included programs for Parkinson’s disease, Alzheimer’s disease and AL amyloidosis. Its investigational therapies include prasinezumab, developed in collaboration with Roche, and programs targeting amyloid beta and transthyretin-related disease.

About Century Therapeutics

Century Therapeutics is a biotechnology company developing cell-based therapies for cancer and other serious diseases. Its research focuses on allogeneic treatments, which are designed to be produced from donor cells rather than made separately for each patient. The company uses induced pluripotent stem cell technology to create immune cells, including natural killer cells and T cells, that can be engineered to recognize and attack disease. Its work includes developing cell therapies with genetic modifications intended to improve their activity and persistence.